Mirum Pharmaceuticals, Inc. Operating Lease, Expense
Mirum Pharmaceuticals, Inc. (MIRM) reported Operating Lease, Expense of $800.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2026-06-30 was $800.00K, a 33.33% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2026-03-31 was $800.00K, a 33.33% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2025-12-31 was $600.00K, a 20.00% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2025-09-30 was $600.00K, a 0.00% change year-over-year.
- Mirum Pharmaceuticals, Inc. operating lease, expense for fiscal 2025 was $2.40M, a 33.33% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. operating lease, expense for fiscal 2024 was $1.80M, a 125.00% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. operating lease, expense for fiscal 2023 was $800.00K, a 0.00% change from fiscal 2022.
- Mirum Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $800.00K, a 14.29% increase from fiscal 2021.
| Period end | Operating Lease, Expense 2 month | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $800.00K 10-Q · filed 2026-08-05 | $1.60M 10-Q · filed 2026-08-05 | $2.20M derived: sum of 3 quarters · filed 2026-08-05 | $2.80M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-06 | $1.40M derived: sum of 2 quarters · filed 2026-05-06 | $2.00M derived: sum of 3 quarters · filed 2026-05-06 | $2.60M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.80M derived: sum of 3 quarters · filed 2026-08-05 | $2.40M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-04 | $1.20M derived: sum of 2 quarters · filed 2026-08-05 | $1.80M 10-Q · filed 2025-11-04 | $2.30M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $600.00K 10-Q · filed 2026-08-05 | $1.20M 10-Q · filed 2026-08-05 | $1.70M derived: sum of 3 quarters · filed 2026-08-05 | $2.30M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-06 | $1.10M derived: sum of 2 quarters · filed 2026-05-06 | $1.70M derived: sum of 3 quarters · filed 2026-05-06 | $2.20M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.10M derived: sum of 2 quarters · filed 2026-02-25 | $1.60M derived: sum of 3 quarters · filed 2026-02-25 | $1.80M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-04 | $1.10M derived: sum of 2 quarters · filed 2025-11-04 | $1.30M 10-Q · filed 2025-11-04 | $1.60M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $500.00K 10-Q · filed 2025-08-06 | $700.00K 10-Q · filed 2025-08-06 | $1.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.20M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-07 | $500.00K derived: sum of 2 quarters · filed 2026-02-25 | $700.00K derived: sum of 3 quarters · filed 2026-02-25 | $900.00K derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $400.00K derived: sum of 2 quarters · filed 2026-02-25 | $600.00K derived: sum of 3 quarters · filed 2026-02-25 | $800.00K 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-12 | $400.00K derived: sum of 2 quarters · filed 2024-11-12 | $600.00K 10-Q · filed 2024-11-12 | $500.00K 10-Q · filed 2023-11-02 | $900.00K derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $200.00K 10-Q · filed 2024-08-07 | $400.00K 10-Q · filed 2024-08-07 | $700.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.30M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-08 | $500.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.10M derived: sum of 3 quarters · filed 2025-02-26 | $1.30M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $900.00K derived: sum of 2 quarters · filed 2025-02-26 | $1.10M derived: sum of 3 quarters · filed 2025-02-26 | $800.00K 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-02 | $200.00K 10-Q · filed 2022-11-09 | $800.00K derived: sum of 2 quarters · filed 2023-11-02 | $500.00K 10-Q · filed 2023-11-02 | $1.20M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-07 | $400.00K 10-Q · filed 2023-08-07 | $600.00K derived: sum of 3 quarters · filed 2024-03-15 | $800.00K derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-04 | $400.00K derived: sum of 2 quarters · filed 2024-03-15 | $600.00K derived: sum of 3 quarters · filed 2024-03-15 | $800.00K derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $400.00K derived: sum of 2 quarters · filed 2024-03-15 | $600.00K derived: sum of 3 quarters · filed 2024-03-15 | $700.00K 10-K · filed 2024-03-15 | |||
| 2021-09-30 | $200.00K 10-Q · filed 2022-11-09 | $400.00K derived: sum of 2 quarters · filed 2022-11-09 | $500.00K 10-Q · filed 2022-11-09 | $700.00K derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $200.00K 10-Q · filed 2022-08-04 | $300.00K 10-Q · filed 2022-08-04 | $500.00K derived: sum of 3 quarters · filed 2022-08-04 | $700.00K derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-05 | $300.00K derived: sum of 2 quarters · filed 2022-05-05 | $500.00K derived: sum of 3 quarters · filed 2022-05-05 | $700.00K derived: sum of 4 quarters · filed 2022-05-05 | |||
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $300.00K derived: sum of 2 quarters · filed 2022-03-09 | $500.00K derived: sum of 3 quarters · filed 2022-03-09 | $600.00K 10-K · filed 2022-03-09 | |||
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-15 | $400.00K derived: sum of 2 quarters · filed 2021-11-15 | $500.00K 10-Q · filed 2021-11-15 | $700.00K derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $200.00K 10-Q · filed 2021-08-05 | $300.00K 10-Q · filed 2021-08-05 | $500.00K derived: sum of 3 quarters · filed 2021-08-05 | $600.00K derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-06 | $300.00K derived: sum of 2 quarters · filed 2021-05-06 | $400.00K derived: sum of 3 quarters · filed 2021-05-06 | $500.00K derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $200.00K derived: sum of 2 quarters · filed 2021-03-09 | $300.00K derived: sum of 3 quarters · filed 2021-03-09 | $300.00K 10-K · filed 2021-03-09 | |||
| 2019-09-30 | $100.00K 10-Q · filed 2020-11-12 | $200.00K derived: sum of 2 quarters · filed 2020-11-12 | $200.00K 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | $100.00K 10-Q · filed 2020-08-06 | $100.00K 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | $100.00K 10-Q · filed 2020-05-07 | ||||||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |